

**Zambia**  
**Support for Human Papillomavirus Vaccine (HPV)**

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Zambia						
<b>2. Routine vaccines grant number:</b> 1923-ZMB-19b-X <b>Routine vaccine introduction grant:</b> 19-ZMB-08f-Y						
<b>3. Date of Decision Letter:</b> 31 October 2018						
<b>4. Date of the Partnership Framework Agreement:</b> 22 October 2014						
<b>5. Programme title:</b> New Vaccine Support (NVS), HPV Routine						
<b>6. Vaccine type:</b> HPV						
<b>7. Requested product presentation and formulation of vaccine:</b> <i>HPV Quadrivalent, 1 dose(s) per vial, LIQUID</i>						
<b>8. Programme duration<sup>1</sup>:</b> 2019 -2023						
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)						
	2019	2020	2021	2022	2023	Total <sup>2</sup>
Programme Budget (Routine) (US\$)	2,267,000	1,821,500	1,804,000	1,598,000	1,711,500	9,202,000
<b>10. Vaccine introduction grant (in US\$):</b>						
						2019
						US\$592,462
<b>11. Operational support for Multi Age Cohort :</b> Not applicable						
<b>12. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>3</sup>						
<b>Type of supplies to be purchased with Gavi funds in each year (Routine)</b>						2019
Number of HPV vaccines doses						497,900
Annual Amounts (US\$)						US\$2,267,000
<b>13. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.						
<b>14. Self-procurement:</b> Not applicable						
<b>15. Co-financing obligations:</b> Reference code: 1923-ZMB-19b-X-C According to the co-financing policy, the Country falls within the group Preparatory transition.						

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the amount that Gavi has approved.

**15. Co-financing obligations:** Reference code: 1923-ZMB-19b-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year. <sup>4</sup>

Type of supplies to be purchased with Country funds each year	2019	2020	2021	2022
Number of vaccine doses	102,400	97,600	115,400	136,000
Number of AD syringes	108,300	102,300	120,900	142,500
Number of safety boxes	1,200	1,150	1,350	1,575
Value of vaccine doses (US\$)	US\$460,460	US\$438,936	US\$519,006	US\$550,544
Total co-financing payments (US\$) (including freight)	US\$471,000	US\$449,000	US\$531,000	US\$564,500

**16. Additional reporting requirements:**

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May of each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**17. Financial clarifications:** Not applicable

**18. Other conditions:** The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.

**On behalf of Gavi**

Signed by,

Hind Khatib-Othman  
 Managing Director, Country Programmes  
 31 October 2018

<sup>4</sup> Co-Financing applies only to the routine cohort. (Multi age cohort is fully financed by Gavi)